Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting fir...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) Vol. 387; no. 10024; pp. 1163 - 1177
Main Authors: James, Nicholas D, Sydes, Matthew R, Clarke, Noel W, Mason, Malcolm D, Dearnaley, David P, Spears, Melissa R, Ritchie, Alastair W S, Parker, Christopher C, Russell, J Martin, Attard, Gerhardt, de Bono, Johann, Cross, William, Jones, Rob J, Thalmann, George, Amos, Claire, Matheson, David, Millman, Robin, Alzouebi, Mymoona, Beesley, Sharon, Birtle, Alison J, Brock, Susannah, Cathomas, Richard, Chakraborti, Prabir, Chowdhury, Simon, Cook, Audrey, Elliott, Tony, Gale, Joanna, Gibbs, Stephanie, Graham, John D, Hetherington, John, Hughes, Robert, Laing, Robert, McKinna, Fiona, McLaren, Duncan B, O'Sullivan, Joe M, Parikh, Omi, Peedell, Clive, Protheroe, Andrew, Robinson, Angus J, Srihari, Narayanan, Srinivasan, Rajaguru, Staffurth, John, Sundar, Santhanam, Tolan, Shaun, Tsang, David, Wagstaff, John, Parmar, Mahesh K B
Format: Journal Article
Language:English
Published: England Elsevier Ltd 19.03.2016
Elsevier Limited
Elsevier
Subjects:
ISSN:0140-6736, 1474-547X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first